RT Book, Section
A1 Panus, Peter C.
A1 Jobst, Erin E.
A1 Masters, Susan B.
A1 Katzung, Bertram
A1 Tinsley, Suzanne L.
A1 Trevor, Anthony J.
SR Print(0)
ID 6090455
T1 Chapter 5. Drugs Affecting the Cholinergic System
T2 Pharmacology for the Physical Therapist
YR 2009
FD 2009
PB The McGraw-Hill Companies
PP New York, NY
SN 978-0-07-146043-9
LK accessphysiotherapy.mhmedical.com/content.aspx?aid=6090455
RD 2024/04/19
AB When  synaptic  transmission  depends  upon  acetylcholine  as  the  primary  neurotransmitter,  it  is  labeled  cholinergic.  The  termination  of  acetylcholine  activity  is  mediated  by  the  enzymeacetylcholinesterase.  There  are  two  subtypes  of  cholinergic  receptors,  muscarinic  (M)  and  nicotinic  (N).  Agonists  that  mimic  the  effects  of  acetylcholine  are  defined  as  cholinomimetics.  Some  drugs  are  direct-acting  agonists  for  the  cholinergic  receptors  (Figure  5–1).  Other  drugs  function  as  indirect-acting  agonists  by  preventing  the  inactivation  of  acetylcholine.  Antagonists  that  inhibit  acetylcholine  at  muscarinic  or  nicotinic  receptors  are  defined  as  anticholinergics.  Drugs  that  selectively  inhibit  muscarinic  receptors  are  called  antimuscarinics  (Figure  5–2),  whereas  those  that  selectively  inhibit  nicotinic  receptors  are  antinicotinics.